The market expects Harrow (HROW) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on March 2, might help the stock move higher if these key numbers are better tha ...

Core Viewpoint - Harrow, a leading provider of ophthalmic disease management solutions in North America, will report its financial results for Q4 and the full year of 2025 on March 2, 2026, and will host a conference call on March 3, 2026, to discuss these results and provide a business update [1]. Group 1: Financial Reporting - The financial results for the fourth quarter and year ended December 31, 2025, will be announced after market close on March 2, 2026 [1]. - A Letter to Stockholders for the fourth quarter will be posted on the "Investors" section of Harrow's website [1]. Group 2: Conference Call Details - A conference call and live webcast will take place at 8:00 a.m. Eastern Time on March 3, 2026, to discuss the financial results and provide a business update [1]. - Participants can access the live webcast on the "Investors" page of Harrow's website, and a replay will be available for one year [2]. - Telephone participants must register in advance to receive a unique dial-in number and PIN for accessing the call [2]. Group 3: Company Overview - Harrow, Inc. is a prominent provider of ophthalmic disease management solutions, offering a comprehensive portfolio of products for various eye conditions, including dry eye disease, age-related macular degeneration, cataracts, refractive errors, glaucoma, and other ocular surface and retina diseases [3]. - The company is committed to delivering safe, effective, accessible, and affordable medications to enhance patient compliance and improve clinical outcomes [3].

Core Insights - Harrow has launched a new Direct-to-Prescriber (DTP) cash-pay offering called PharmaPack, aimed at providing affordable FDA-approved ophthalmic products as alternatives to off-label compounded formulations [1][2]. Product Offering - PharmaPack kits are designed to enhance access to FDA-approved ophthalmic products for millions of Americans needing infection control and treatment of pain and inflammation related to cataract surgery [2]. - The kits simplify the prescribing process by eliminating insurance-related administrative complexities and reducing regulatory and medical-legal risks associated with off-label compounded products [2]. Market Demand - The PharmaPack program addresses a significant challenge in ophthalmology by providing reliable and affordable FDA-approved therapies, which has been a request from optometrists [4]. - The offering is expected to foster greater confidence among prescribers when considering FDA-approved branded alternatives to compounded products [4]. Availability and Expansion - Initially, PharmaPack kits will be available in California, Mississippi, Arkansas, Connecticut, and Alabama, with plans for nationwide expansion in the coming weeks [6].

Core Viewpoint - Harrow (HROW) shares experienced a significant increase of 9.7% to $44.9, following the company's reaffirmation of its revenue guidance for full-year 2025 and ongoing progress in its commercial and development initiatives [1][2]. Group 1: Company Performance - Harrow plans to double its VEVYE sales team, expand IHEEZO into office-based care, and double the surgical sales force for TRIESENCE [2]. - The company is expected to report quarterly earnings of $0.35 per share, reflecting a year-over-year increase of 40%, with revenues projected at $87.5 million, up 30.9% from the same quarter last year [3]. - The consensus EPS estimate for Harrow has been revised 117.4% higher over the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4]. Group 2: Industry Context - Harrow operates within the Zacks Medical - Drugs industry, where another company, Assertio (ASRT), saw a 3.9% increase in its stock price, closing at $12.24, and has returned 28.9% over the past month [5]. - Assertio's consensus EPS estimate has decreased by 1.4% over the past month to -$3.05, representing a significant decline of 84.9% compared to the previous year [6].

Financial Guidance - Harrow, Inc. reaffirmed its full-year 2025 revenue guidance of between $270 million and $280 million[5] Leadership Appointment - Patrick W. Sullivan was appointed as Chief Commercial Officer, bringing over 25 years of commercial leadership experience[7] Compensation Details - Mr. Sullivan's base salary is set at $425,000 per year, with a target annual bonus opportunity of 40% of base compensation[12] - The company will grant Mr. Sullivan 40,000 restricted stock units (RSUs), with 25,000 RSUs vesting when revenue reaches $230 million in a calendar quarter[12]

Core Insights - Harrow reaffirms its full-year 2025 revenue guidance of $270-280 million, highlighting strong execution across commercial and development programs [1] - The company is on track to double its VEVYE sales force, expand IHEEZO into office-based settings, and double the TRIESENCE sales force in surgical settings [1][2] - Harrow's ImprimisRx has settled regulatory matters with the California Board of Pharmacy and will exit the California market while focusing on other states [1][10] VEVYE Sales Force Expansion - Harrow plans to double the VEVYE sales force from approximately 50 to 100 territories by Memorial Day 2026, driven by recent coverage wins and expected stabilization of net pricing [3] IHEEZO Commercial Expansion - The company is expanding IHEEZO's focus to the office-based setting, targeting over 2.5 million annual procedures, which is expected to accelerate demand and adoption [4] TRIESENCE Sales Force Expansion - Harrow intends to double the surgical sales force for TRIESENCE, responding to positive clinical feedback and increasing demand metrics for the product [6] OneHarrow Initiative - The OneHarrow initiative aims to unify branding and operations under a single organization to enhance patient access, affordability, and clinical outcomes [7] Leadership Changes - Patrick W. Sullivan has been promoted to Chief Commercial Officer, focusing on strengthening Harrow's commercial foundation and aligning with the company's revenue goals [8] MELT-300 and MELT-210 Programs - Harrow is on track to submit New Drug Applications for MELT-300 and MELT-210, with all necessary studies initiated [1][9] ImprimisRx Regulatory Settlement - ImprimisRx has settled with the California Board of Pharmacy, agreeing to a fine of approximately $157,000, and will exit the California market effective February 1, 2026 [10]

Core Viewpoint - The article discusses the investment position of the analyst in HROW, indicating a beneficial long position through various means such as stock ownership and derivatives [1]. Group 1 - The analyst expresses personal opinions regarding HROW and clarifies that they are not receiving compensation for the article, except from Seeking Alpha [1]. - There is an emphasis on the importance of individual due diligence for readers before making investment decisions, highlighting that the commentary is not personalized investment advice [2]. - The article notes that past performance is not indicative of future results, and any views expressed may not reflect the opinions of Seeking Alpha as a whole [3].

Company Overview - Harrow, Inc. is an eyecare pharmaceutical company focused on the discovery, development, and commercialization of ophthalmic pharmaceutical products, having transformed from a controversial compounder to a leading specialty pharma platform in U.S. eye care [2][4] - Founded in 2012 by Mark Baum, the company shifted from custom formulations to acquiring and scaling FDA-approved ophthalmic drugs through its own commercial infrastructure [2] Business Model - Harrow operates a three-segment model: Branded Pharmaceuticals, ImprimisRx, and Strategic Holdings, creating a self-reinforcing ecosystem that enhances physician relationships and drives growth through branded drugs [3] - The "Access for All" program serves as an in-house reimbursement engine, facilitating rapid adoption and high retention among doctors and patients [4] Financial Performance - Harrow has achieved compounding revenue growth exceeding 40% annually since 2014, supported by a disciplined acquisition strategy focused on late-stage or under-commercialized assets [4] - The company targets over $1 billion in annualized revenue and 30-40% EBIT margins by 2027, driven by expanding dry-eye penetration and entry into the $12 billion retina market [5] Market Position - With a market cap of under $1.4 billion, Harrow trades at approximately 5 times its estimated 2028 EBIT, indicating it operates as a scaled ophthalmic pharma platform rather than a niche compounder [6] - The investment case is strengthened by founder-led discipline, high insider ownership, and capital-light economics, despite recent stock depreciation of about 8.55% due to rising costs [7]

Company Overview - Harrow (HROW) is a rapidly growing ophthalmic pharmaceutical company focused on providing a wide range of eye care drugs in the United States [1]. Investment Philosophy - The investment approach reflects the teachings of renowned investors such as Warren Buffett and Charlie Munger, emphasizing a long-term value investment strategy [1]. Analyst Background - The analyst has a PhD in theoretical physics from UC Berkeley and has transitioned from a brief career in physics to investing, accumulating experience as an analyst at a billion-dollar fund before starting a small fund in 2009 [1].

Summary of Harrow (NasdaqGM:HROW) FY Conference Call - December 02, 2025 Company Overview - **Company**: Harrow Health, Inc. - **Industry**: Biopharmaceuticals, specifically focusing on ophthalmology and anesthesiology Key Points MELT Acquisition and Technology - The MELT acquisition, closed in mid-November, is seen as a strategic fit to expand into procedural sedation beyond ophthalmology, targeting markets like dental and plastic surgery [5][6][7] - The MELT-300 product aims to reduce opioid exposure in cataract surgeries, with over 90% of patients currently receiving IV fentanyl [6] - The company has a patent portfolio that supports both domestic and international markets [7] - A special protocol agreement (SPA) with the FDA is in place, with efficacy studies completed showing MELT-300's superiority over individual components [8] Commercialization Strategy - Harrow plans to leverage its established infrastructure in ophthalmology while seeking partnerships in non-ophthalmology markets [10][11] - The company has hired Frank Mullery, a former Mylan executive, to enhance its access to the hospital market [10] Product Pipeline - **MELT-210**: Positioned as an oral dissolving tablet for sedation, targeting a wide range of procedures and potentially tens of millions of use cases [12][14][15] - **Vevye**: A product for dry eye disease that has nearly doubled its market share in recent quarters due to a significant coverage win, allowing for easier patient access [16][18][20] - **IHEEZO**: A topical anesthetic for intravitreal injections, expected to generate around $50 million in revenue for the year, with a goal of capturing 10% market share by 2027 [27][28][29] - **TRIESENCE**: After a disappointing start, the product is showing signs of recovery with new commercial leadership and a focus on full-label promotion [30][31][32] Biosimilars Strategy - Harrow plans to enter the biosimilar market with ranibizumab and aflibercept, aiming to create a comprehensive solution for retinal practices [34][36] - The company expects to capture a modest market share, focusing on quality and service rather than competing aggressively with existing products [39][40] Access Programs - The Harrow Access for All program aims to ensure that patients have access to medications with minimal out-of-pocket costs, achieving over 90% coverage for key products [42][44] Business Development and M&A - The company is open to further business development and M&A opportunities, particularly if they can acquire valuable assets at favorable prices [45] Additional Insights - The company emphasizes a patient-centric approach in its product development and marketing strategies, aiming to improve patient experiences across its offerings [6][16][27] - Harrow's focus on building a comprehensive suite of products for surgical and retinal markets positions it well for future growth [35][36] This summary encapsulates the key insights from the conference call, highlighting Harrow's strategic initiatives, product developments, and market positioning within the biopharmaceutical industry.